Post by icemandios on Apr 18, 2023 12:36:32 GMT
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
PR Newswire
- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 -
MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Intratumoral administration of the PD-1/CTLA-4 INTASYL improved tumor control compared to either single targeting formulation, at an identical total dose. The dual-targeting formulation was well tolerated.
"The synergistic effects of dual inhibition of PD-1 and CTLA-4 in enhancing tumor response are clinically recognized, however, a high rate of immune-related adverse events limits the utility of systemic use of this combination of products," said Dr. Mary Spellman , Phio's Acting Chief Medical Officer. "Intratumoral administration of dual-targeting PD-1/CTLA-4 INTASYL may provide an effective treatment option, with an improved safety profile."
Presentation Details:
Poster Title: INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4
provides synergistic antitumor efficacy in the treatment of murine colon cancer
in vivo
Session Date and Time: Tuesday, April 18, 2023 from 1:30 PM - 5:00 PM EST
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
- Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 -
MARLBOROUGH, Mass. , April 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Intratumoral administration of the PD-1/CTLA-4 INTASYL improved tumor control compared to either single targeting formulation, at an identical total dose. The dual-targeting formulation was well tolerated.
"The synergistic effects of dual inhibition of PD-1 and CTLA-4 in enhancing tumor response are clinically recognized, however, a high rate of immune-related adverse events limits the utility of systemic use of this combination of products," said Dr. Mary Spellman , Phio's Acting Chief Medical Officer. "Intratumoral administration of dual-targeting PD-1/CTLA-4 INTASYL may provide an effective treatment option, with an improved safety profile."
Presentation Details:
Poster Title: INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4
provides synergistic antitumor efficacy in the treatment of murine colon cancer
in vivo
Session Date and Time: Tuesday, April 18, 2023 from 1:30 PM - 5:00 PM EST
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com .